A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
暂无分享,去创建一个
G. Luporini | C. Gridelli | V. Lorusso | M. de Lena | M. Lena | C. Oliva | G. Frassineti | M. Pacini | M. Antimi | C. F. Pollera | C. F. Pollera
[1] R. Dreicer,et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Shepherd,et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.
[3] A. Harris,et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.
[4] T. Kuzel,et al. 1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study , 1995 .
[5] A. Harris,et al. Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Roth. Preliminary experience with paclitaxel in advanced bladder cancer. , 1995, Seminars in oncology.
[7] B. Roth. Palliative chemotherapy in advanced bladder cancer. , 1995, Seminars in oncology.
[8] R. Dreicer,et al. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Neijt,et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. , 1994, Journal of the National Cancer Institute.
[10] M. Dimopoulos,et al. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. , 1994, The Journal of urology.
[11] A. Ceribelli,et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] D. V. Von Hoff,et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. , 1994, European journal of cancer.
[13] Y Z Xu,et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.
[14] L. Hertel,et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.
[15] S. Mineishi,et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Igawa,et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. , 1990, The Journal of urology.
[17] L. Hertel,et al. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). , 1990, Cancer research.
[18] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.
[19] I. Tannock,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.
[20] V. Heinemann,et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.